CD4+ T Cells Prevent Spontaneous Experimental Autoimmune Encephalomyelitis in Anti–Myelin Basic Protein T Cell Receptor Transgenic Mice by Van de Keere, Fabienne & Tonegawa, Susumu
 
1875
 
J. Exp. Med. 
 
Ó
 
 The Rockefeller University Press • 0022-1007/98/11/1875/08 $2.00
Volume 188, Number 10, November 16, 1998 1875–1882
http://www.jem.org
 
CD4
 
1
 
 T Cells Prevent Spontaneous Experimental
Autoimmune Encephalomyelitis in Anti–Myelin Basic
Protein T Cell Receptor Transgenic Mice
 
By Fabienne Van de Keere and Susumu Tonegawa
 
From the Howard Hughes Medical Institute, the Center for Cancer Research, and the Department of 
Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139
 
Summary
 
Autoimmune diseases result from a failure of tolerance. Although many self-reactive T cells are
present in animals and humans, their activation appears to be prevented normally by regulatory
T cells. In this study, we show that regulatory CD4
 
1
 
 T cells do protect mice against the spon-
taneous occurrence of experimental autoimmune encephalomyelitis (EAE), a mouse model for
multiple sclerosis. Anti–myelin basic protein (MBP) TCR transgenic mice (T/R
 
1
 
) do not
spontaneously develop EAE although many self-reactive T cells are present in their thymi and
peripheral lymphoid organs. However, the disease develops in all crosses of T/R
 
1
 
 mice with
recombination-activating gene (RAG)-1 knockout mice in which transgenic TCR-expressing
cells are the only lymphocytes present (T/R
 
2
 
 mice). In this study, crosses of T/R
 
1
 
 mice with
mice deficient for B cells, CD8
 
1
 
 T cells, NK1.1 CD4
 
1
 
 T (NKT) cells, 
 
g
 
/
 
d
 
 T cells, or 
 
a
 
/
 
b
 
 T
cells indicated that 
 
a
 
/
 
b
 
 CD4
 
1
 
 T cells were the only cell population capable of controlling the
self-reactive T cells. To confirm the protective role of CD4
 
1
 
 T cells, we performed adoptive
transfer experiments. CD4
 
1
 
 T cells purified from thymi or lymph nodes of normal mice pre-
vented the occurrence of spontaneous EAE in T/R
 
2
 
 mice. To achieve full protection, the cells
had to be transferred before the recipient mice manifested any symptoms of the disease. Trans-
fer of CD4
 
1
 
 T cells after the appearance of symptoms of EAE had no protective effect. These
results indicate that at least some CD4
 
1
 
 T cells have a regulatory function that prevent the
activation of self-reactive T cells.
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everal mechanisms of tolerance normally prevent the
immune system from responding to self-antigens. In the
thymus, tolerance is induced by negative selection of de-
veloping T cells with high affinity to self-antigens (1).
Low-affinity self-reactive T cells, or T cells expressing a re-
ceptor for antigens not presented intrathymically, escape to
the peripheral tissues. Although some self-reactive T cells
are prevented from causing disease by T cell anergy (2) or
apoptosis (3), others appear to remain silent simply because
the antigens they recognize are not present in immuno-
genic forms. Interestingly, a high incidence of autoimmune
diseases has been observed in rodents rendered lymphopenic
(for review see reference 4). In these models, the spontane-
ous activation of disease-causing T cells has been attributed
to the lack of regulatory CD4
 
1
 
 T cells (5, 6).
CD4
 
1
 
 T cells can develop into functionally distinct pop-
ulations that differ in their patterns of cytokine production.
Th1 cells secrete proinflammatory cytokines such as IFN-
 
g
 
and TNF-
 
b
 
 and are responsible for certain organ-specific
autoimmune diseases such as multiple sclerosis, diabetes,
and rheumatoid arthritis. Th2 cells produce IL-4, IL-5, IL-6,
IL-10, and IL-13. These cytokines activate B cells and en-
hance eosinophil proliferation and function. The cytokines
produced by Th1 and Th2 cells antagonize each other’s de-
velopment and activity (7). Because of this cross-regulation
between the Th1 and Th2 subsets, it was thought that Th1
cell–mediated autoimmune diseases could be prevented or
cured by Th2 cells. However, using a mouse model for
multiple sclerosis, experimental autoimmune encephalo-
myelitis (EAE),
 
1
 
 we could not show a protective function
of anti–myelin basic protein (MBP) Th2 cells (8). Indeed
anti-MBP Th2 cells not only failed to protect mice against
 
1
 
Abbreviations used in this paper:
 
 CNS, central nervous system; EAE, exper-
imental autoimmune encephalomyelitis; KO, knockout; MBP, myelin
basic protein; NOD, nonobese diabetic; RAG, recombination-activating
gene.
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pathogenic anti-MBP Th1 cells but did themselves induce
EAE, at least in immunodeficient mice. Pakala et al. made
similar observations using nonobese diabetic (NOD) mice (9).
In this work, we used the EAE model to characterize the
regulatory lymphocytes that normally prevent disease in-
duction by autoreactive T cells. EAE is caused by CD4
 
1
 
 T
cells that recognize peptides derived from proteins of the
central nervous system (CNS) in association with MHC
class II molecules. Paralysis results from T cell infiltration in
the CNS and subsequent degradation of myelin. The dis-
ease can be induced in susceptible animals by immunization
with CNS proteins such as MBP or by transfer of encepha-
litogenic T cell lines (10), or may occur spontaneously in
mice expressing a transgenic TCR specific for MBP (Ac1-
11) (11, 12). Interestingly, Lafaille et al. (12) observed a
striking difference in the incidence of spontaneous EAE in
anti-MBP TCR transgenic mice, referred to hereafter as
T/R
 
1
 
 mice, and their crosses with recombination-activat-
ing gene (RAG)-1 deficient mice, referred to hereafter as
T/R
 
2
 
 mice. Although EAE occurred in only 
 
z
 
10% of the
T/R
 
1
 
 mice, all T/R
 
2
 
 mice became sick. This finding indi-
cated that lymphocytes present in the T/R
 
1
 
 mice but ab-
sent in the T/R
 
2
 
 mice were able to control the self-reac-
tive anti-MBP T cells. Having already ruled out a role of
anti-MBP Th2 cells in this protection (8), we now show,
by crossing the T/R
 
1
 
 mice with mice deficient in subsets
of lymphocytes and by adoptive transfer experiments, that
CD4
 
1
 
 T cells carrying receptors other than the MBP-spe-
cific TCR prevent the spontaneous development of EAE
in anti-MBP TCR transgenic mice.
 
Materials and Methods
 
Mice.
 
Anti-MBP TCR transgenic mice have been described
previously (12). Mice expressing a TCR specific for MBP Ac1-
11 were generated in C57BL/6 mice. These mice were crossed
to mouse strains with various gene defects, all on a C57BL/6
background. The IA
 
u
 
 restriction element was introduced by
crosses with B10.PL mice. H-2
 
u/u
 
 mice were used in all experi-
ments. The B10.PL(73NS)/Sn, 
 
b
 
2-microglobulin (
 
b
 
2-m) knock-
out (KO), TCR-
 
a
 
 KO, and IgM 
 
m
 
 KO mice were obtained
from The Jackson Laboratory (Bar Harbor, ME). The RAG-1
KO and TCR-
 
d
 
 KO mice were available in our laboratory. All
mice were maintained in autoclaved cages with autoclaved bed-
ding, food, and water. Animals were typed for the expression of
the transgenic TCR by flow cytometry analysis of blood lympho-
cytes using anti-V
 
b
 
8.1, 8.2-FITC, and anti–CD4–PE antibodies
(PharMingen, San Diego, CA). Flow cytometry analysis and PCR
were used to determine the expression of the RAG-1, IgM 
 
m
 
,
TCR-
 
a
 
, and 
 
b
 
2-m genes. The expression of the TCR-
 
d
 
 gene
was determined by PCR only. Two sets of primers, one set span-
ning the disrupted site of the specific gene and another set span-
ning the neomycin resistance marker, were used to perform the
PCR reactions. Flow cytometry analysis of blood lymphocytes
using anti-CD3–FITC and anti-B220–PE antibodies (PharMin-
gen) determined the expression of the RAG-1 and IgM 
 
m
 
 genes.
TCR-
 
a
 
 and 
 
b
 
2-m gene expression was established by using the
anti-CD8–FITC and anti-CD3–PE antibodies (PharMingen).
 
CD4
 
1
 
 T Cell Purification.
 
Peripheral CD4
 
1
 
 T cells were pu-
rified from pooled mandibular, axillar, inguinal, and mesenteric
lymph nodes of female B10.PL mice by depletion of CD8
 
1
 
 T
cells, 
 
g
 
/
 
d
 
 T cells, and B cells. CD4
 
1
 
CD8
 
2
 
 thymocytes were pu-
rified from thymi of female B10.PL mice by depletion of CD8
 
1
 
T cells and 
 
g
 
/
 
d
 
 T cells. Single-cell suspensions were prepared,
and after lysis of RBCs, CD4
 
1
 
 T cells were purified by magnetic
sorting with a SuperMacs (Miltenyi Biotec, Sunnyvale, CA) using
magnetic microbeads as previously described (13). The cells were
first labeled for 45 min at 4
 
8
 
C with biotinylated anti–
 
g
 
/
 
d
 
-TCR
antibody (GL3; PharMingen), then washed and incubated for 20
min at 4
 
8
 
C with a mixture of streptavidin-coupled beads and
beads directly coupled to anti-CD8 antibodies (Miltenyi Biotec).
Washed cells were passed through a column inserted into the Su-
perMacs magnet, and the cells that did not bind to the column
(CD4
 
1
 
) were collected. For the purification of the CD4
 
1
 
 T cells
from lymph nodes, beads directly coupled to anti-B220 antibod-
ies were added to the labeling mixture. To evaluate the efficiency
of the cell separation, aliquots of purified cells were stained with
anti-CD3–FITC and anti-CD4–PE antibodies (PharMingen) and
analyzed by flow cytometry. Typically, we obtained a purity 
 
.
 
95
or 
 
.
 
70% for CD4
 
1
 
 T cells isolated from lymph nodes or thymi,
respectively.
 
Flow Cytometry.
 
CD4
 
1
 
 T cells either just before the transfer
or recovered from mesenteric lymph nodes of EAE-free mice 9 wk
after the transfer were analyzed by using fluorochrome-conju-
gated antibodies against CD3 (145-2C11), CD4 (RM4-5),
V
 
b
 
8.1,8.2 (MR5-2), CD45RB (23G2), CD44 (IM7), and CD62L
(MEL-14), all from PharMingen, and CD4 (CT-CD4), from
Caltag (Burlingame, CA). About 0.5 
 
3
 
 10
 
6
 
 cells were incubated
with antibodies for 45 min at 4
 
8
 
C, washed, and analyzed with a
FACScan
 
Ò
 
 and the CellQuest software (Becton Dickinson,
Mountain View, CA). Dead cells were excluded based either on
Figure 1. Incidence of spontaneous EAE in anti-MBP TCR transgenic
RAG-11/2 (T/R1) and RAG-12/2 (T/R2) mice. (a) Percentage of mice
with EAE among T/R1 (white bar, n 5 45), and T/R2 (striped bar, n 5
30) mice. All mice were monitored for EAE symptoms for at least 5 mo
starting at 1 mo of age unless they developed EAE and died. (b) Time
course of the development of spontaneous EAE in T/R2 mice. 
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propidium iodide staining or on their forward and side scatter
profiles.
 
Cell Transfer.
 
Purified CD4
 
1
 
 T cells were washed twice with
PBS and injected intravenously into T/R
 
2
 
 recipient mice in 200 
 
m
 
l
of PBS.
 
EAE Scoring.
 
Clinical symptoms of EAE were graded as fol-
lows (14): level 0, no symptoms; level 1, limp tail; level 2, partial
paralysis of hind legs; level 3, complete paralysis of hind legs; level
4, paralysis of fore and hind legs; level 5, moribund.
 
Results
 
EAE Develops Spontaneously in T/R
 
2
 
 Mice at a Narrow
Age Window.
 
We crossed the T/R
 
1
 
 mice in a C57BL/6-
B10.PL background with RAG-1–deficient mice (15) in a
C57BL/6 background. The incidence of spontaneous EAE
was 100% in T/R
 
2
 
 littermates but only 4.4% in T/R
 
1
 
 lit-
termates (Fig. 1 
 
A
 
). In T/R
 
2
 
 mice the disease developed in
a narrow time window (Fig. 1 
 
B), between days 35 (no dis-
ease) and 65 (100% disease incidence). This result indicated
that T/R1 mice contain regulatory cells that prevent the
anti-MBP T cells from becoming pathogenic, and protect
the T/R2 mice from an early onset of the disease.
The Absence of CD41 T Cells in Anti-MBP TCR Trans-
genic Mice Abrogates the Protection against Spontaneous EAE.
T/R1 mice differ from T/R2 mice in that they have B
cells, CD81 T cells, some CD41 T cells expressing non-
transgenic T cell receptor chains, NK1.1 CD41 T cells
(NKT cells), and g/d T cells. To investigate the putative
protective role of any of these lymphocyte subsets, we
crossed the T/R1 mice to several mouse strains, each of
which lacked one or more lymphocyte subsets due to a
gene KO. All strains of mice used for these crosses were in
a C57BL/6 background. In each cross we compared the
disease incidence of anti-MBP TCR transgenic littermates
homozygous and heterozygous for the disrupted gene. We
did not observe a significant difference in the incidence of
EAE in the anti-MBP TCR transgenic mice that lacked B
cells, CD81 T cells, or g/d T cells due to the targeted dis-
ruption of the IgM m chain gene (16), the b2-m gene (17),
Figure 2. Incidence of spontaneous EAE in various KO mice carrying
the anti-MBP TCR transgene. The incidence of EAE was monitored in
H-2u/u anti-MBP TCR transgenic mice that were homozygous (2/2) or
heterozygous (1/2) for the disruption of the gene indicated on top of
each figure. All mice were monitored for signs of disease for at least 5 mo
starting at 1 mo of age unless they developed EAE and died. The number
of mice observed with EAE as well as the total number of mice in each
group is indicated at the top of each bar. Disease incidences between each
1/2 and 2/2 group were compared using the normal-theory method.
The only statistical difference observed was between the TCR a 1/2
and 2/2 groups with a P , 0.001.
Table 1. Protection of T/R2 Mice against EAE after Adoptive Transfer of CD41 T Cells*
Experiment Source of CD41 T cells No. of cells injected EAE incidence (%) Fatality
Individual
maximum score
3 106 %
1 Lymph node 0.5 2/4 (50) 0 2, 0, 0, 2
2 Lymph node 1 1/2 (50) 0 1, 0
3 Lymph node 2.5 3/3 (100) 0 2.5, 2.5, 3
4 Lymph node 2.5 0/2 (0) 0
5 Lymph node 5 0/2 (0) 0
6 Thymus 1 1/2 (50) 0 1, 0
7 Thymus 1 0/2 (0) 0
8 Thymus 1 0/1 (0) 0
9 Thymus 1 0/2 (0) 0
10 Thymus 2.5 3/4 (75) 0 2, 3, 2, 0
11 Thymus 2.5 1/4 (25) 0 0, 0, 1, 0
12 Thymus 5 2/4 (50) 0 1, 0, 0.5, 0
Control – – 14/14 (100) 57 5, 3.5, 5, 2.5, 5, 3.5, 2.5, 3,
5, 5, 5, 5, 3.5, 5
*28–43-d-old mice were injected and monitored every other day for 9 wk.1878 Protection from Autoimmune Encephalomyelitis by CD41 T Cells
or the TCR-d chain gene (18), respectively (Fig. 2). In
contrast, mice homozygous for a mutation in the TCR-a
gene, resulting in the absence of CD41 and CD81 T cells
(19), were not protected. In these mice, the incidence of
spontaneous EAE was similar to that observed in the RAG-
1–defective T/R2 mice (Fig. 2). Taken together, these
data showed that the non-TCR transgenic a/b CD41 T
cells that are present in T/R1 mice but not in T/R2 mice
prevent spontaneous EAE. It should be noted that the inci-
dence of EAE in all mice described above that do have a/b
CD41 T cells was z25%. This is clearly higher than the in-
cidence of EAE in T/R1 mice, which is only 4.4%. We do
not know the reason for this. It could possibly be due to
minor differences in the genetic background that arose in
these crosses. Indeed B6 and B10 mice, although geneti-
cally very close, do differ at multiple loci (20, 21).
Adoptive Transfer of CD41 T Cells Protects Young T/R2
Mice against Spontaneous EAE. To confirm the protective
role of CD41 T cells, we performed adoptive transfer ex-
periments. CD41 T cells were purified from lymph nodes
and thymi of B10.PL mice. Different numbers of these cells
were transferred into young T/R2 mice that did not yet
show any signs of disease. We monitored the reconstituted
T/R2 mice every other day for 9 wk for the spontaneous
development of EAE. The transfer of as few as 106 CD41
T cells protected the recipient T/R2 mice. The protection
was not always completely effective. Some of the recipients
developed mild symptoms and either remained sick or re-
covered from the disease (Table 1, Fig. 3 a). In contrast, the
disease developed in all control T/R2 mice and was lethal
in .50% of them during the observation period of 9 wk
(Table 1). CD41 T cells isolated from both lymph nodes
and thymi were protective (Table 1, Fig. 3 a). No protec-
tion was observed when CD41 T cells were transferred to
T/R2 mice that were already sick at the time of the injec-
tion (data not shown). To assess the time-window during
which protection could be accomplished, we injected 5 3
106 CD41 T cells into groups of T/R2 mice that differed
by age. Protection was observed as long as the recipient mice
were 40 d old or younger (Fig. 3 b). Recipient mice that
were older than 45 d at the time of injection developed
EAE as severely as untreated mice, although mice that were
41–45 d old developed a very mild form of the disease
(mean EAE score of 1.5). Thus, to achieve full protection
the CD41 T cells must be transferred before the T/R2
mice reach the age of 40 d.
We also adoptively transferred CD81 T or B cells in T/R2
mice. All recipients developed EAE symptoms similar to
the uninjected control T/R2 mice (data not shown).
Taken together, these findings showed that CD41 T cells
but no other lymphocyte subsets protect anti-MBP TCR
transgenic mice against spontaneous development of EAE.
After Transfer, Naive CD41 T Cells Acquire a Memory Phe-
notype. We analyzed the phenotype of the CD41 T cells
before transfer and studied their fate in the recipient mice.
A typical CD3/CD4 cytofluorometry profile of the trans-
ferred cells is shown in Fig. 4 A. At the time of injection,
the lymph node cells expressed high levels of CD45RB and
CD62L and an intermediate level of CD44 (Fig. 4 B, a).
This surface marker profile is characteristic of naive T cells
(22). The CD41CD82 thymocytes expressed CD45RB
and CD44 at intermediate levels, and z50% of them ex-
pressed CD62L (Fig. 4 B, b). 9 wk after transfer, the recon-
stituted mice were killed and their T cell populations were
analyzed. The injected CD41 T cells recovered from mes-
enteric lymph nodes constituted z12% of the total T cell
population and had acquired a phenotype of memory T cells
(22): CD45RBlowCD62LlowCD44high (Fig. 5 B, a). Very simi-
lar results were obtained with lymph node T cells from
T/R1 littermates. In these mice, z10% of all CD41 T cells
were nontransgenic and most of them exhibited a memory
phenotype (Fig. 5 B, b).
NKT Cells Do Not Protect against Spontaneous EAE.
NKT cells are a small lymphocyte population that expresses
a Vb8-biased TCR repertoire, and that produces large
amounts of IL-4 after TCR ligation. It is thought that they
Figure 3. Protection of T/R2 mice against EAE by adoptive transfer of
CD41 T cells. (a) 29–41-d-old T/R2 mice were injected with 2.5 3 106
CD41 T cells isolated from lymph nodes (open circle) or from thymi (filled
circle). One mouse injected with thymocytes showed mild symptoms of
EAE (level 1) but quickly recovered. The control noninjected mouse
(filled square) developed severe EAE (level 3.5). (b) Transfer of 5 3 106
CD41 T cells in T/R2 mice grouped by age. Cells isolated from either
lymph nodes or thymi were injected into five T/R2 mice, 30–40 d old
(filled square), seven T/R2 mice, 41–45 d old (open diamond), and seven
T/R2 mice, .45 d old (cross). Among the three groups of 19 treated ani-
mals, 8 and 11 mice received cells isolated from lymph nodes and thymi,
respectively. 13 control mice received no injection (open circle).1879 Van de Keere and Tonegawa
may play a role in autoimmunity (23). A small number of
NKT cells were present in the protective CD41 T cell
population that we transferred in T/R2 mice. They consti-
tuted z0.1 and z2% of the cells purified from the lymph
nodes and thymocytes, respectively (data not shown). How-
ever, it is unlikely that these cells played a role in the pro-
tection against spontaneous EAE. First, despite the 20-fold
difference of concentration of NKT cells between the
transferred peripheral T cell and the thymocytes, both pop-
ulations were equally competent in the protection. Second,
although b2-m–deficient mice lacked NKT cells (24), we
did not observe any difference of disease susceptibility be-
tween transgenic mice heterozygous and homozygous for
the defect of the b2-m gene (Fig. 2).
Discussion
Using the EAE model, Lafaille et al. showed that most
mice carrying a transgenic TCR specific for MBP did not
spontaneously develop EAE despite the presence of many
self-reactive T cells (12). Interestingly, the disease devel-
oped in all crosses of T/R1 mice with RAG-1 KO mice
(T/R2 mice), indicating that regulatory lymphocytes must
exist and control the spontaneous development of EAE. In
this work we showed that the striking difference between
the incidence of spontaneous EAE in T/R2 and in T/R1
mice was due to the presence of protective CD41 T cells in
the latter mice. Protection against EAE was lost in T/R1
mice crossed to homozygosity for a defect in the TCR-a
gene. Crosses of T/R1 mice with mice deficient for other
Figure 4. Flow cytometry analysis of
the donor CD41 T cells. (A) CD4/CD3
profile of aliquots of the donor cells iso-
lated from lymph nodes (a) or from
thymi (b) of female B10.PL mice. The
percentage of CD41CD31 T cells is in-
dicated at the upper right corner of each
panel. (B) Histograms of the expression
of the indicated markers on the surface
of the CD41-gated donor cells from
lymph nodes (a) or thymi (b).
Figure 5. Flow cytometry analysis of
lymphocytes recovered from a T/R2 recip-
ient of CD41 T cells and from a T/R1 lit-
termate. (A) CD4/Vb8.2 profile of mesen-
teric lymph node lymphocytes from a T/R2
recipient mouse 9 wk after the transfer of
CD41 T cells from lymph nodes of B10.PL
mice (a), and from an age-matched T/R1
littermate that received no injection (b).
The percentage of CD41Vb8.22 (i.e.,
CD41 nontransgenic cells) and CD41
Vb8.21 (i.e., mostly CD41 transgenic cells)
is indicated on each panel at the upper left
and right quadrants, respectively. (B) Histo-
grams (filled area) of the expression of the in-
dicated markers on the surface of the
CD41Vb8.22-gated mesenteric lymph
node lymphocytes from a T/R2 recipient
mouse 9 wk after the transfer of CD41 T
cells from lymph node cells, or from a T/R1
littermate (b). In B (a), the histograms of the
donor cells shown in Fig. 4 B, a are repro-
duced for comparison (open area). The ex-
periments were carried out with 11 T/R2 recipient mice and with 5 T/R1 littermates. The data shown are representative of these experiments. Similar
experiments were also carried out with mesenteric lymph node lymphocytes from T/R2 mice that received CD41 T cells from B10.PL thymi. The re-
sults were similar to those shown here in part a of A and B.1880 Protection from Autoimmune Encephalomyelitis by CD41 T Cells
genes that resulted in the lack of B cells, CD81 T cells,
NKT cells, or g/d T cells had no significant effect on the
incidence of spontaneous EAE. This indicated that CD41
T cells must be responsible for the protection observed in
T/R1 mice. The ability of CD41 T cells to protect against
EAE was confirmed by the adoptive transfer of such cells,
purified from normal mice, into T/R2 mice. This demon-
strated that the protective cells develop not only in the
T/R1 mice but also in normal nontransgenic mice. To
achieve full protection, the cells had to be transferred be-
fore anti-MBP TCR-expressing cells had caused any dis-
ease symptoms. Apparently the protective T cells prevented
the MBP-reactive T cells from expressing their disease-
inducing potential. They could not suppress already ongo-
ing responses of pathogenic T cells (our unpublished data),
nor could they protect T/R1 mice against EAE induced by
immunization with MBP (25). The inability of regulatory
CD41 T cells to suppress already activated disease-causing
cells was also observed by their failure to protect recipient
mice of in vitro–activated encephalitogenic T cell clones
against EAE (8, 10).
The CD41 cells we injected contained a small percent-
age of NK1.1 CD41 T cells. However, our data did not
support a role for these cells in the protection against EAE.
In contrast to our results, Hammond et al. have shown that
NOD mice could be protected from diabetes upon adop-
tive transfer of a/b-TCR1CD42CD82 thymocytes (NKT
cells) through their secretion of IL-4 (26), and Wilson et al.
have observed a reduced frequency of NKT cells and a loss
of their capacity to secrete IL-4 in diabetic patients (27).
Even though a reduced frequency of NKT cells has been
observed in mice (28, 29) and humans (30) prone to au-
toimmune diseases, thus far no report has shown a de-
creased frequency of NKT cells in multiple sclerosis pa-
tients. It is unlikely that NKT cells play a protective role in
every autoimmune disease.
The most extensively studied model of a spontaneous
autoimmune disease is the diabetes of NOD mice. The NOD
mouse model differs from our EAE mouse model in that
diabetes occurs with high frequency in non-TCR trans-
genic mice. However, diabetes development is accelerated
in NOD mice expressing a transgenic TCR derived from a
diabetogenic T cell clone (31). A recent study by Luhder et al.
(32) has shown that diabetes development is delayed and its
incidence is reduced in these TCR transgenic mice if the
development of more endogenous CD41 T cells was pro-
moted by crossing them to mice with an alternate MHC
class II locus. The protective effect of the mixed MHC
class II loci was reversed in mice that were homozygous for
a defect in the TCR-a gene. The authors concluded that
the spontaneous development of diabetes was delayed and
prevented, in at least some mice, by regulatory CD41 T
cells (32). However, they did not address the role of CD81
T cells in the protection observed. Indeed, the crosses they
performed affected not only the CD41 but also the CD81
T cell population. Although the number of CD81 T cells
was increased in crosses with an alternate MHC class II lo-
cus, no CD81 T cells were present in the crosses with the
TCR-a defect. Thus, a protective role for CD81 T cells
can not be ruled out in this model of autoimmune diabetes.
We observed that in T/R1 mice, which do not develop
spontaneous EAE at a high frequency despite the presence
of high numbers of anti-MBP TCR transgenic T cells, most
non-TCR transgenic CD41 T cells expressed memory cell
markers. This is similar to the findings that, in mice carry-
ing a transgenic TCR recognizing pigeon cytochrome c,
the transgenic cells maintain a naive phenotype throughout
their lives, whereas the endogenous CD41 T cells have a
memory phenotype (33). In our transfer experiments, pro-
tection against spontaneous EAE was achieved by the in-
jection of thymic and peripheral CD41 T cells expressing a
naive phenotype. However, 9 wk after the transfer, most
of these cells had acquired markers of memory cells:
CD45RBlowCD62LlowCD44high. This is probably the result
of an extensive proliferation of the injected cells, which
give rise to memory-phenotype cells (34). The spontaneous
development of autoimmune diseases has also been observed
in other animal models, and protection against these diseases
was accomplished by transfer of memory CD41 T cells.
Diabetes developed in rats rendered lymphopenic by adult
thymectomy and sublethal g irradiation. The disease could
be completely prevented by the injection of CD41 T cells
that expressed CD45RC at low levels, a marker for memory
T cells (5). Protection by memory CD41 T cells has also
been observed in a model of inflammatory bowel disease. This
disease was induced in SCID mice by the transfer of CD41
CD45RBhigh (naive) T cells. Transfer of CD41CD45RBlow
T cells not only did not result in disease, but also protected
against disease induction by CD41CD45RBhigh T cells (6).
In a series of experiments with the same TCR transgenic
mouse model used in our study but conducted indepen-
dently, Olivares-Villagomez et al. also found that CD41 T
cells protect T/R2 mice against spontaneous EAE (35).
In this study we have examined the role of each of the
major classes of lymphocytes in the development of EAE.
Tolerance could be reestablished and autoimmune disease
prevented by reconstituting T/R2 mice with CD41 T
cells. This model will be helpful to study the specificity of
the regulatory cells and the mechanism by which they pro-
tect against autoimmune diseases.
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